Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.73 |
| ▸ | MGLL | Q99685 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8577619 | 0.91 | SMN1; SMN2 (0.70) | NQO2MGLLHSD17B10NPC1RAB9A | |
| Acetanilide SCHEMBL6693944 | 0.90 | HSD17B10 (0.76) | NQO2MGLLHSD17B10NPC1RAB9A | |
| SCHEMBL1749196 | 0.88 | MEN1 (0.59) | NQO2MGLLNPC1RAB9ATSHR | |
| Biphenyl SCHEMBL9009636 | 0.88 | NAPRT (0.86) | NQO2HSD17B10NPC1RAB9ANAPRT | |
| SCHEMBL12999591 | 0.87 | NPC1 (0.69) | NQO2MGLLHSD17B10NPC1RAB9A | |
| SCHEMBL14384612 | 0.86 | CNR1 (0.71) | SMN1; SMN2CYP17A1CYP11B1CYP11B2HSD17B1 | |
| SCHEMBL969807 | 0.86 | RAB9A (0.65) | NQO2MGLLHSD17B10NPC1RAB9A | |
| SCHEMBL694904 | 0.86 | NQO2 (0.56) | NQO2MGLLHSD17B10NPC1RAB9A | |
| SCHEMBL4654909 | 0.86 | ALDH1A1 (0.67) | NQO2MGLLHSD17B10NPC1RAB9A | |
| SCHEMBL10663620 | 0.86 | CYP17A1 (0.76) | NQO2MGLLHSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007130743-A2 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | NQO2 2041/4885MGLL 1314/4885HSD17B10 1100/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | NQO2 1172/4885MGLL 4654/4885HSD17B10 1152/4885 |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | NQO2 1501/4885MGLL 3372/4885HSD17B10 1022/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | NQO2 1172/4885MGLL 4654/4885HSD17B10 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.